Medical Doctor Program year 2023 Reported 2019–2023 Source: CMS Open Payments, 2026 publication

Gregory Legris

Pediatric Pulmonology Phoenix, AZ Medical Doctor

NPI 1336112192 CMS profile 287403

500 W Thomas Rd, Suite 200, Phoenix, AZ 85013

Open in the dashboard

General payments

$7,755

262 records reported · program years 2019–2023

Research payments

$0

Paid to them · None reported · program years 2019–2023

Ownership & investment interest

$0

None reported

Through program year 2023, Gregory Legris of Phoenix, AZ is reported in the CMS Open Payments database as having received $7,755 across 262 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 90th percentile of Pediatric Pulmonology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2023 General $509 17
2022 General $3,139 67
2021 General $1,320 68
2020 General $1,004 44
2019 General $1,783 66

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Gregory Legris
  • Pediatric Pulmonology median
  • Middle half of Pediatric Pulmonology
  • National median

In program year 2025, general payments to Gregory Legris were reported at $0. Among 622 Pediatric Pulmonology profiles paid that year, the median was $139 and the middle half received between $60 and $405.

Show as a table
Year Gregory Legris Pediatric Pulmonology median Middle half National median
2019 $1,783 $151 $59–$495 $163
2020 $1,004 $107 $34–$339 $114
2021 $1,320 $125 $40–$511 $132
2022 $3,139 $133 $49–$428 $149
2023 $509 $138 $44–$494 $160
2024 $0 $132 $46–$398 $164
2025 $0 $139 $60–$405 $169

Breakdown

Who paid General payments · program years 2019–2023
  1. Genzyme Corporation $2,234 38 payments
  2. AstraZeneca Pharmaceuticals LP $1,207 37 payments
  3. GlaxoSmithKline, LLC. $864 35 payments
  4. Regeneron Healthcare Solutions, Inc. $576 17 payments
  5. Chiesi USA, Inc. $443 39 payments
  6. AbbVie, Inc. $383 22 payments
  7. Genentech USA, Inc. $347 7 payments
  8. Philips Electronics North America Corporation $246 11 payments
  9. Amgen Inc. $238 2 payments
  10. Pharming Healthcare, Inc. $178 4 payments
  11. Other $1,039 50 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2023
  1. Food and Beverage $6,351 246 payments
  2. Consulting Fee $1,263 1 payment
  3. Education $141 15 payments
Products named General payments · program years 2019–2023
  1. DUPIXENT Immunology $2,162 34 payments
  2. DUPIXENT Inflammation And Immunology $576 17 payments
  3. NUCALA Immunology $438 24 payments
  4. NUCALA Respiratory $426 11 payments
  5. PERTZYE $408 31 payments
  6. TEZSPIRE $385 12 payments
  7. CREON $383 22 payments
  8. FASENRA $345 7 payments
  9. SYMBICORT $328 14 payments
  10. BETHKIS $265 15 payments
  11. Other $2,263 99 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

262 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Pediatric Pulmonology in Arizona

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2023

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record